LEADER 04100nam 2201057z- 450 001 9910557152603321 005 20231214133619.0 035 $a(CKB)5400000000040531 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68644 035 $a(EXLCZ)995400000000040531 100 $a20202105d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aFree Radical Research in Cancer 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 electronic resource (192 p.) 311 $a3-03936-088-4 311 $a3-03936-089-2 330 $aCancer is a great challenge to efficient therapy due to biological diversity. Disturbed oxidative homeostasis in cancer cells certainly contributes to differential therapy response. Further, one of the hallmarks of cancer cells is adaptation which includes fine tuning of the cellular metabolic and signalling pathways as well as transcription profiles. There are several factors which contribute to the tumor diversity and therapy response, and oxidative stress is certainly one of them. Changes in oxygen levels due to hypoxia/reoxygenation during tumor growth modulate antioxidative patterns finally supporting increased cell diversity and adaptation to stressing conditions. Additionally, cancer chemotherapy based on ROS production can also induce also adaptation. To counteract these negative effects natural products are often used for their antioxidant activities as well as photodynamic therapy supported by novel chemosensitizers. Understanding of possible pathways which can trigger antioxidant defence at a certain time during cancer development can also provide possible strategies in fighting cancer. 606 $aTechnology: general issues$2bicssc 610 $aNQO1 610 $aNQO1*2 610 $apolymorphism 610 $aquinone 610 $abreast cancer 610 $amenadione 610 $alapachone 610 $adoxorubicin 610 $aascorbate 610 $aoxidative stress 610 $areactive oxygen species 610 $asperm 610 $acancer chemotherapy 610 $aantioxidant therapy 610 $aantioxidant proteins 610 $achemoresistance 610 $aoxaliplatin 610 $a5-Fluorouracil 610 $amyelodysplastic syndromes 610 $acarbonylation 610 $adeferasirox 610 $aovary 610 $acalcium channel 610 $aTrolox 610 $agranulosa cell tumor 610 $acell death 610 $amitochondria 610 $aphotodynamic therapy 610 $asinglet oxygen 610 $anitric oxide 610 $alight 610 $acombination therapy 610 $aantioxidants 610 $ableomycin 610 $acancer treatment 610 $achemotherapy-induced toxicity 610 $acisplatin 610 $afree radicals 610 $amethotrexate 610 $aozone therapy 610 $alung cancer 610 $acancer metabolism 610 $areactive oxygen species (ROS) 610 $atherapy resistance 610 $anew therapeutic strategies 610 $abreast cancer stem cells 610 $a4-hydroxy-2-nonenal 610 $aextracellular matrix 610 $aNRF2 610 $abardoxolone methyl 610 $aprostate cancer 610 $acastration-resistant prostate cancer 610 $aandrogen receptor (AR), AR-V7 610 $aanti-androgen 610 $aenzalutamide 610 $aandrogen deprivation therapy 610 $acancer 610 $aantioxidant 610 $atriphala 610 $aayurveda 610 $achemoprevention and chemotherapy 615 7$aTechnology: general issues 700 $aC?ipak Gas?parovic?$b Ana$4edt$01310428 702 $aC?ipak Gas?parovic?$b Ana$4oth 906 $aBOOK 912 $a9910557152603321 996 $aFree Radical Research in Cancer$93029801 997 $aUNINA